Norman Wolmark, MD, FACS, FRCSC
Chairman, NSABP Foundation
Norman Wolmark, MD, is the chairman of the NSABP Foundation and chair and contact principal investigator of NRG Oncology, one of five research groups in the NCI’s National Clinical Trials Network. He is currently Professor of Surgery and Director of NCI Cooperative Group Clinical Trials at the UPMC Hillman Cancer Center and the University of Pittsburgh.
Dr. Wolmark has spent decades conducting groundbreaking research and clinical trials in the treatment of breast and bowel cancers. Many of his early studies were conducted at the University of Pittsburgh alongside Bernard Fisher, MD, one of the founders of the NSABP. Findings from NSABP trials led to the establishment of lumpectomy plus radiotherapy over radical mastectomy as the standard surgical treatment for breast cancer; were the first to demonstrate that adjuvant therapy could alter the natural history of breast cancer, increasing survival rates; and were the first to demonstrate on a large scale the preventive effects of the drug tamoxifen and raloxifene in breast cancer.
Dr. Wolmark is a Fellow of the American College of Surgeons and of the Royal College of Surgeons (Canada) and a member of a number of professional associations and organizations including the American Society for Clinical Oncology, the American Association of Cancer Research, and the American Surgical Association. He has authored more than 400 scientific publications and has served on the editorial boards of the Journal of Clinical Oncology, The New England Journal of Medicine, and Breast Cancer Research and Treatment.